Qualigen Therapeutics Inc
Change company Symbol lookup
Select an option...
QLGN Qualigen Therapeutics Inc
EFC Ellington Financial Inc
FITB Fifth Third Bancorp
AWAY ETFMG Travel Tech ETF
CO Global Cord Blood Corp
KRP Kimbell Royalty Partners LP
VIRX Viracta Therapeutics Inc
ONFO Onfolio Holdings Inc
DCPH Deciphera Pharmaceuticals Inc
MET MetLife Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancer. The Company's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.

Closing Price
$1.27
Day's Change
0.0161 (1.29%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.28
Day's Low
1.20
Volume
(Light)
Volume:
38,230

10-day average volume:
69,761
38,230

Company Profile

Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancer. The Company's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
1.04x
Price/Book (MRQ)
0.43x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

January 2023
Current Month
177.2K
Previous Month
95.9K
Percent of Float
4.63%
Days to Cover
0.1296 Days

Share Information

QLGN is in a share class of common stock
Float
3.8M
Shares Outstanding
4.2M
Institutions Holding Shares
26
5.55%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Michael S. PoirierChmn.
  • Amy BroidrickPres.
  • Christopher L. LotzCFO
  • Shishir K. SinhaCOO
  • Tariq ArshadSr.VP

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.